Just occurred to me putting up on Zenodo might also be option? (from what I recall that goes almost instant and you get DOI) Quite funny they didn’t take (they rejected reviews by me before). Medarxiv can be even more picky (and funny), they wanted us once to replace “..a 25 year old woman..” with “a patient who identified as female between the age of 20 and 30…” so the reader cannot possibly identify the person. I mean who reads this and thinks “…you know that patient with the abnormal frequency-wavevector scaling of plasma viscosity in that pre-print? Well, that can only be Caroline from Tuesday Yoga class!” From: Kareem Elsayad <kareem.elsayad@meduniwien.ac.at> Date: Tuesday, 9. September 2025 at 11:45 To: Software Mailing list <software@biobrillouin.org> Subject: Re: [EXTERN] [Software] Fwd: BIORXIV/2025/674600 -- Please Resubmit Yes, I agree – let’s do arXiv then. From: Robert Prevedel via Software <software@biobrillouin.org> Reply to: Robert Prevedel <prevedel@embl.de> Date: Tuesday, 9. September 2025 at 10:06 To: Software Mailing list <software@biobrillouin.org> Subject: [EXTERN] [Software] Fwd: BIORXIV/2025/674600 -- Please Resubmit Dear all, please see below - surprisingly bioRxiv does not think our manuscript fits and they require more analysis/data. Shall we quickly submit to arXiv instead? Just let me know! Best, Robert -- Dr. Robert Prevedel Group Leader and Senior Scientist Cell Biology and Biophysics Unit European Molecular Biology Laboratory Meyerhofstr. 1 69117 Heidelberg, Germany Phone: +49 6221 387-8722 Email: robert.prevedel@embl.de http://www.prevedel.embl.de Begin forwarded message: From: bioRxiv@openrxiv.org Subject: BIORXIV/2025/674600 -- Please Resubmit Date: 9. September 2025 at 08:33:58 WEST To: prevedel@embl.de, prevedel@embl.de MS ID#: BIORXIV/2025/674600 MS TITLE: A standardized file format and open-source analysis framework for Brillouin microscopy data Dear Robert Prevedel; Thank you for submitting your manuscript to bioRxiv. bioRxiv is intended for complete research papers with new data/analysis rather than announcements of tools/resources/reagents and your submission falls into this category. We are, therefore, returning the manuscript to give you the opportunity to add analyses/data to support the utility of your tool/resource. This data can be added as supplemental information. If you decide to make these edits, please resupply your manuscript to the above manuscript ID BIORXIV/2025/674600. Please do not submit the manuscript as a new submission with a different manuscript ID number as this will delay screening. You will find this manuscript in the "Papers returned for your attention" section of your author area. Please contact us if you have any questions. The bioRxiv team _______________________________________________ Software mailing list -- software@biobrillouin.org To unsubscribe send an email to software-leave@biobrillouin.org